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Abstract: Fospropofol, a phosphorylated prodrug version of the popular induction agent propofol, 
is hydrolyzed in vivo to release active propofol, formaldehyde, and phosphate. Pharmacodynamic 
studies show fospropofol provides clinically useful sedation and EEG/bispectral index suppres-
sion while causing significantly less respiratory depression than propofol. Pain at the injection 
site, a common complaint with propofol, was not reported with fospropofol; the major patient 
complaint was transitory perianal itching during the drug’s administration. Although many 
clinicians believe fospropofol can safely be given by a registered nurse, the FDA mandated that 
fospropofol, like propofol, must be used only in the presence of a trained anesthesia provider.
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Introduction
The concept of moderate sedation and analgesia, introduced to replace the more arcane 
term conscious sedation, has been generally accepted in the anesthesia community 
as an appropriate target for sedation by nonanesthesiologists. Moderate sedation as 
defined by the American Society of Anesthesiologists (ASA) requires that the patient 
be arousable to verbal commands or light tactile stimulation. A patent airway, as well 
as stable cardiac and respiratory functions, are maintained throughout the period of 
sedation (Table 1).1 Moderate sedation is not synonymous with monitored anesthesia 
care (MAC); the former can be administered by anyone capable of giving the medica-
tions and monitoring the patient,2 while MAC must be performed under the medical 
direction of an anesthesiologist. The scope of MAC is significantly wider, including 
the necessity of a preoperative evaluation, an anesthesiologist’s personal participa-
tion or medical direction of the entire plan of care, and the ability to rescue a patient 
from unintended deep sedation or to intentionally provide deep sedation or general 
anesthesia if clinically warranted.
There is a common armamentarium of drugs shared between providers of moder-
ate sedation and MAC, all given with the intent of maximizing anxiolysis and amnesia 
while maintaining a verbal patient. The ability of the patient to speak and understand is 
useful not only as a monitor of sedation depth and cardiorespiratory function but is also 
necessary to offer reassurance and communicate to the patient when active cooperation 
is required during the procedure (eg, breath holding).3 Hypnotic agents may be employed 
during MAC to bring the patient to a level of deep anesthesia/analgesia. Propofol, a short-
acting anesthetic agent that is rapidly titratable, is currently the premier agent chosen to 
achieve this purpose. Qualities such as a quick recovery time (even after a prolonged Therapeutics and Clinical Risk Management 2009:5 950
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infusion) and the fact that the drug is not associated with nausea 
or emesis have further augmented its popularity.
Propofol was first introduced into clinical practice in 1986 
by AstraZeneca under the trade name Diprivan® (a shortened 
version of DI-isoPRopyl IV ANesthetic.) It was marketed as 
an agent for the induction and maintenance of general anes-
thesia as part of a balanced technique, as well as the short 
term (72 hours) sedation of mechanically ventilated adults 
in the intensive care setting. Its popularity and safety profile 
resulted in its adoption in many sites outside of the operating 
room and ICU, and it soon became the drug of choice for 
providing sedation to patients undergoing minimally inva-
sive and uncomfortable procedures such as bronchoscopy, 
transesophageal echocardiography, and colonoscopy.4 As 
such, it supplanted the standard regimens of intravenous 
benzodiazepine/narcotic combinations and the DTP cocktail 
(meperidine, promethazine, and chlorpromazine).5 Patients 
reported a high degree of satisfaction with propofol and 
regained consciousness quickly, thereby facilitating their 
discharge and speeding flow through a busy medical site.6 
Although economic savings were garnered through reduced 
PACU stays, the necessity of trained personnel to deliver 
propofol added another layer of cost to the procedure. As per 
the package insert: “DIPRIVAN 2% should be given by those 
trained in anesthesia (or, where appropriate, doctors trained in 
the care of patients in intensive care). Patients should be con-
stantly monitored and facilities for maintenance of a patent 
airway, artificial ventilation and oxygen enrichment and other 
resuscitative facilities should be readily available at all times. 
DIPRIVAN 2% should not be administered by the person 
conducting the diagnostic or surgical procedure.”7 In the case 
of colonoscopies, gastroenterologists estimate that the need 
for an anesthesiology provider adds between US$250 and 
US$400 to the cost of every procedure.8 This has galvanized 
many physicians, especially gastroenterologists, to petition 
the FDA to revise the requirement for a practitioner trained 
in anesthesia. As evidence, they cite several large studies9–12 
that document the safety of RN-administered propofol in the 
absence of an anesthesiologist. The ASA continues to support 
the current safety recommendations.13
Despite its widespread clinical use, propofol is not a drug 
that is free of unwanted side effects. Perhaps the most ubiquitous 
is pain at the injection site,14 a phenomenon that is unreliably 
reduced by the addition of lidocaine to the propofol solution 
prior to injection or by the injection of lidocaine into the vein 
prior to propofol. (The only technique shown to reliably reduce 
pain on injection in a majority (60%) of patients is to apply a 
tourniquet to the proximal arm and administer lidocaine 0.5 mg/
kg 30 to 120 seconds prior to the propofol.)15 Propofol infu-
sion syndrome, a rare but reported condition, includes severe 
metabolic acidosis, rhabdomyolysis, renal failure, and cardiac 
failure in association with a prolonged propofol infusion, critical 
illness, and the concurrent administration of catecholamines and 
steroids.16 The lipid emulsion formula introduces another set of 
concerns including the need for absolute sterility when handling 
the drug, the relatively short window of usage (6 hours) when 
Table 1 Definitions of clinical states of sedation as proposed by the American society of anesthesiologist’s task force on sedation and 
analgesia by non-anesthesiologists
Sedation level Characteristics
Minimal sedation/anxiolysis A drug-induced state during which patients respond normally to verbal commands. 
Cognitive function and coordination may be impaired. 
ventilatory and cardiovascular functions are unaffected.
Moderate sedation/analgesia A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, 
either alone or accompanied by light tactile stimulation. 
No interventions are required to maintain a patent airway and spontaneous ventilation is adequate. 
Cardiovascular function is usually maintained.
Deep sedation/analgesia A drug-induced depression of consciousness during which patients cannot be easily aroused but respond 
purposefully following repeated or painful stimulation. 
Ability to independently maintain ventilatory function may be impaired. 
Patients may require assistance in maintaining a patent airway and spontaneous ventilation may be inadequate. 
Cardiovascular function is usually maintained.
General anesthesia A drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation. 
Ability to independently maintain ventilatory function is often impaired. 
Patients often require assistance in maintaining a patent airway and positive pressure ventilation may be required 
because of depressed spontaneous ventilation or drug-induced depression of neuromuscular function. 
Cardiovascular function may be impaired.
Reproduced with permission from Practice guidelines for sedation and analgesia by non-anesthesiologists.   An updated report by the American Society of Anesthesiologists 
Task Force on sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002;96:1004–1017.1 Copyright © 2002 wolters Kluwer Health.Therapeutics and Clinical Risk Management 2009:5 951
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the vial is opened, and the hypertriglyceridemia seen in patients 
receiving propofol infusion in the ICU setting.17–19 Finally, 
propofol itself has a remarkably narrow therapeutic window; 
even in trained hands, the dose curve bridging moderate 
sedation to general anesthesia may be unexpectedly steep. In 
susceptible patients, propofol is known to cause dose-dependent 
hemodynamic20 and respiratory21 depression and possibly loss 
of airway protective reflexes22 in doses commonly used for 
mild to moderate sedation.
The stage was therefore set to develop a milder form 
of propofol – one with less pronounced cardiorespiratory 
depression, preferably delivered in an aqueous form to 
eliminate the problems associated with the lipid emulsion. 
Investigators had proven that hydrophobic drugs could be 
made water-soluble by the addition of a large hydrophilic 
group, typically a phosphate monoester or a hemisuccinate, 
to create a prodrug. The hydrophilic addition was then 
enzymatically cleaved in vivo releasing the active drug. This 
approach has been used successfully with a variety of drug 
classes including antibiotics and steroids,23 and more recently 
in the development of the anticonvulsant drug phosphenytoin. 
Initial animal studies were performed by annexing propofol 
with a variety of water-soluble side groups.24–30 Researchers 
reported success in the formulation of propofol phosphate, 
a water-soluble prodrug which reliably produced sedation in 
small mammals typical of that seen with propofol injection.31 
This was followed by the development of Aquavan® 
(Guilford Pharmaceuticals, Baltimore, MD), initially 
referred to as GPI 15715. Chemically this water-soluble 
prodrug undergoes hydrolysis by alkaline phosphatase 
(predominantly at the endothelial cell surface) to release the 
active metabolite propofol, formaldehyde, and phosphate 
(Figure 1.) The liberated formaldehyde is rapidly converted 
to formate. Sedation and anesthesia are reliably produced 
among animals32 as well as human33 subjects.
Pharmacokinetics
The pharmacokinetics of fospropofol have been extensively 
studied in both laboratory animals as well as humans, and 
details have been incorporated into a web based simulation 
comparing fospropofol to propofol.35 In humans, a dual com-
partment model for the central distribution of the drugs was 
devised33,34,36 where the concentration of fospropofol in the 
central compartment was a function of the injected dose (D), 
and the concentration of propofol in the central compartment 
was a function of its conversion from fospropofol calculated 
in mass per time as F × kmet × CGPI × VCGPI, where F equals 
the fraction of the dose of fospropofol that is metabolized to 
propofol, kmet is the elimination rate constant of the prodrug, 
CGPI is its plasma concentration, and VCGPI is the volume of 
distribution of fospropofol in the central compartment. CGPI 
is measured directly, VCGPI and kmet are estimated, and F is 
calculated using the molecular weights of fospropofol and 
propofol (332 and 178, respectively) assuming a complete 
conversion. The data also implicated the presence of periph-
eral compartments for both drugs, and nonlinear regression 
suggested the best fit for the data relied upon the presence 
of two peripheral compartments for each of the drugs, with 
transfer rate constants between the central and peripheral 
spaces designated as k12 and k21, k13 and k31, etc. (Figure 2).
Further examination of the pharmacodynamics of fos-





















Figure 1 The conversion of fospropofol into its metabolites. Reproduced with permission from Gibiansky e, Struys M, Gibiansky L, vanluchene A, et al. Aquavan® injection, 
a water-soluble prodrug of propofol, as a bolus injection: a phase i dose-escalation comparison with Diprivan® (Part 1 – Pharmacokinetics). Anesthesiology. 2005;103:718–729.34 
Copyright © 2002 wolters Kluwer Health.Therapeutics and Clinical Risk Management 2009:5 952
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drug, with a steep initial decline (representing fast elimination 
and redistribution within a small volume of distribution) 
followed by a slower second phase decline of secondary 
elimination and conversion. The gender of the volunteer was 
found to have no effect upon the pharmacokinetic profile.34 
The liberated propofol, as expected, displayed typical lipo-
philic pharmacodynamics with large volumes of distribution. 
However, propofol derived from the parent prodrug showed 
significant differences in pharmacodynamic properties from 
Diprivan®, namely a larger volume of distribution, lower peak 
plasma concentrations, and a shorter half-life due to a more 
rapid clearance. These differences were initially attributed to 
differences in sampling procedures and study design. It was 
later realized that an error in the assay37 invalidated all of the 
quantitative pharmacokinetic data related to fospropofol. In 
all of the studies previously referenced samples of blood were 
collected in tubes containing a powdered form of sodium 
orthovanadate (SOV) to inhibit the alkaline phosphatase 
enzyme and therefore preclude the further conversion of 
fospropofol into propofol. Careful examination, however, 
later revealed incomplete dissolution of the powder resulting 
in various concentrations of SOV, thereby affecting plasma 
pH and in some instances causing hemolysis. Because these 
factors were neither known nor controlled at the time of the 
studies, all data derived relating to the propofol concentra-
tions could therefore be inaccurate, and is therefore now 
considered invalid. However the quantitative data relating 
to fospropofol itself is legitimate, as it was not affected by 
the assay. Repeated assays using liquid SOV, which would 
preclude this problem, have been suggested, but at the time 
of this writing they have yet to be published.
Urine samples have also been studied to test for the 
excretion of unchanged fospropofol. Fewer than 5% of the 
samples revealed the presence of the compound in the urine, 
and the majority of those were from volunteers receiving 
fospropofol in the higher dose range. From these data, the 
fraction of unchanged fospropofol excreted in the urine is 
estimated at 0.02%.34
When fospropofol is converted to its active metabolite 
propofol, formate is released from the parent compound. 
In previous research formate, in high concentrations, has 
been shown to result in acidosis, ketonemia and acetonuria, 
respiratory compromise, and blindness.38 In controlled 
studies it was demonstrated that no significant difference in 
intravenous formate levels existed between patients receiving 
fospropofol or Diprivan®. Furthermore, the level of intrave-
nous formate was not found to vary with increasing doses 
of either of the induction agents.34
Pharmacodynamics
The pharmacodynamic properties of fospropofol have been 
studied using both noncompressed EEG evaluation39 as well 
as bispectral index (BIS) monitoring. Initial dose escalation 

































Figure 2 Some investigators suggest that fospropofol exists in a single peripheral compartment, thereby resulting in a 5-compartment model. Others33 postulate a dual 
peripheral compartment for fospropofol, suggesting a 6-compartment model (shown).Therapeutics and Clinical Risk Management 2009:5 953
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divided into 3 groups of 3 volunteers.33 Each group received 
a fospropofol infusion over a 10-minute period, with the first 
group receiving a total dose of 290 mg each, the second group 
receiving 580 mg each, and the final group receiving 1160 mg 
each. The volunteers were tested for loss of consciousness 
(LOC) as defined in this study by the absence of a response to 
a loud verbal command. If LOC was documented, the patient 
was further tested for a corneal reflex response, defined in 
this study as being a physical response to having a wisp of 
cotton rubbed across the cornea.
Among the group receiving 290 mg of fospropofol, no 
LOC was documented. One patient in this group reported 
an unpleasant sensation of tingling and burning in the anal 
and genital area lasting approximately 5 minutes which 
resolved without therapy. Among the 3 patients receiving 
580 mg, 1 experienced LOC 12 minutes after the initiation 
of the infusion and return to consciousness (ROC) was noted 
22 minutes after the start of the infusion. Blood concentra-
tions of propofol were obtained corresponding to LOC and 
ROC, but the aforementioned error in propofol analysis has 
invalidated the accuracy of these measurements. Amongst the 
highest dose group all 3 patients displayed LOC 9 ± 3 minutes 
after the start of the infusion. ROC occurred 24 ± 2 minutes 
after fospropofol infusion was initiated. In this group one 
patient again complained of a burning sensation in the 
anogenital region, spontaneously resolving after 2 minutes. 
Among the 4 patients who experienced LOC, the adminis-
tered dose of fospropofol was 870 ± 237 mg (mean ± SD). 
The corneal reflex was lost in only 1 patient, a member of 
the 1160 mg group.
All 9 subjects were also evaluated using the Observer’s 
Assessment of Alertness/Sedation (OAA/S) Scale.40 The 
scale was evaluated at 2, 5, 10, 20, 60, 120, and 240 minutes 
after the conclusion of the infusion (for patients who experi-
enced no LOC) or after ROC. Patients were graded on a scale 
from 1 (deep sleep) to 5 (completely alert). The low dose 
group achieved a score of 5 in 25 ± 5 minutes, the middle 
dose group at 63 ± 49 minutes, and the high dose group at 
112 ± 72 minutes.
The authors of the study also sought to measure the 
hemodynamic effects of fospropofol on the 9 volunteers. 
While one subject in the 580 mg group displayed an eleva-
tion in systolic blood pressure throughout the entire study 
period, the remaining subjects all showed a decrease in both 
systolic and diastolic pressures in the range of 20% to 25%. 
(In order of ascending dose, the values were S: –18% ± 7%, 
D: –13% ± 9% for Group 1; S: –18% ± 15%, D: –29% ± 7% 
for Group 2; S: –25% ± 8%, D: –28% ± 9% for Group 3). 
Blood pressure values reached their nadir at 20 ± 8 minutes 
after the beginning of fospropofol infusion and returned 
to baseline approximately 60 minutes after the start of 
the infusion. All subjects showed an increase in heart rate 
(in order of ascending dose, +36% ± 17%, +32% ± 4%, 
and +52% ± 35%) including 1 volunteer in Group 3 who 
had an elevation of heart rate from 43 to 83 beats per minute. 
Heart rate reached its maximum value at 12 ± 8 minutes after 
the initiation of fospropofol infusion and returned to baseline 
at approximately 30 minutes after the start of the infusion.
In addition, respiratory and metabolic parameters were 
also measured. In all 9 subjects oxygen saturation dropped to 
a minimum value of 94.6% ± 1.6%, reached 15 ± 3 minutes 
after the beginning of the fospropofol infusion. All 3 patients 
in the 1160 mg dose group required insufflation of oxygen 
via a nasal cannula secondary to an oxygen saturation via 
pulse oximetry of less than 93%. Apnea was not observed 
in any of the subjects. An arterial blood sample drawn 
from each volunteer at the end of the infusion revealed a 
dose dependent rise in PaCO2 in the 3 ascending dosage 
categories to 38.2 ± 2.7, 42.9 ± 0.9, and 47.1 ± 4.8 mm Hg 
respectively. Body temperature remained constant in all 
subjects at 36.2 ± 0.4 °C.
It is difficult to compare these physiologic results to 
what one would find in patients who received an equipotent 
dose of propofol in lipid emulsion. Prior studies involved 
infusion of propofol over longer time intervals (Forrest et al 
delivered 500 mg of propofol over 30 minutes and reported 
a drop in systolic blood pressure of 22%, a diastolic drop of 
28%, and an increase in pulse rate of 12%).41 Other authors 
report a more modest drop of systolic BP of 15%,42 but the 
achieved concentration may not correlate with the fospro-
pofol study.
The same authors expanded upon their study protocol 
the following year by studying pharmacodynamics not 
only in terms of clinical signs of sedation, but also by 
collecting EEG and BIS data.36 Again 9 male volunteers 
were recruited in the study. In this protocol, each volunteer 
received a propofol lipid emulsion infusion over 60 minutes 
with the dose adjusted to obtain a specific plasma propofol 
concentration. For the first 20 minutes of the infusion, the 
target plasma concentration was 5 µg/mL; this was reduced 
to 3 µg/mL for the next 20 minutes and 1.5 µg/mL for the 
final 20 minutes. The rationale behind the varying target 
plasma concentrations was to more accurately measure 
clinical pharmacodynamic effects.43 A constant infusion, 
if set too low, may not produce the desired clinical signs. 
Alternately, if it is set too high the clinical signs may occur Therapeutics and Clinical Risk Management 2009:5 954
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in such rapid succession that it is difficult or impossible 
to correlate the pharmacodynamic effect with the plasma 
concentration of the drug. Patients were monitored for 
physiologic signs as well as signs of sedation identical to 
the monitoring described in the authors’ previous study. 
In addition, EEG monitoring was started 30 minutes prior 
to the beginning of the infusion and continued until the 
patient was alert as determined by the OAA/S Scale. BIS 
monitoring via an Aspect A1000® monitor (Aspect Medical 
Systems, Norwood MA) was also performed during this 
interval.
The same subjects were brought back at least 14 days 
later to repeat the study; this time, however, they received 
a continuous 60-minute infusion of fospropofol. The aim of 
the study was to adjust the drug concentration to replicate 
the plasma propofol concentration in the identical 3 inter-
vals: 20 minutes at 5 µg/mL, 20 minutes at 3 µg/mL, and 
20 minutes at 1.5 µg/mL. However, due to the previously 
discussed problem with SOV, the measured propofol con-
centrations may have been incorrect, falsely suggesting an 
equivalence in dosage between propofol lipid solution and 
fospropofol when such an equivalence didn’t exist.
The EEG results for the propofol group showed initial 
high activity in the α band with a median frequency (MEF) 
of 9 to 10 Hz. Within 5 minutes of beginning the infusion 
β activity began to appear with a concomitant drop in the 
MEF to 2.5 Hz. This was followed by a shift to the slower 
θ and δ wavelengths. As the propofol plasma concentration 
was dropped during the second 20 minute interval the MEF 
was noted to increase to 3.5 Hz, and it continued to trend 
towards baseline during the third 20 minute interval. No 
burst suppression was noted during the 1-hour infusion. Out 
of the 9 volunteers, 6 dropped their BIS from initial read-
ings of approximately 90 to minimum values of 50 to 60. 
One patient began with a baseline BIS reading of 75, and 
the 2 remaining volunteers never dropped their BIS below 
80. When the patients later received fospropofol the EEG 
showed a more rapid decrease in MEF, dropping quickly to 
1 Hz and remaining less than 3 Hz throughout the duration 
of the infusion. β activity was not noted as the patients pro-
gressed directly to the θ and δ wavelengths, although burst 
suppression was present in several volunteers. MEF did 
not return to baseline until approximately 30 minutes after 
the cessation of the infusion. For the fospropofol group the 
reduction in BIS was of a comparable amount, although the 
slope of the drop was steeper and the duration was prolonged 
versus the propofol group. Again, the equivalence of dosing 
cannot be relied upon.
Hemodynamic and respiratory parameters were similar 
between the two series, with blood pressure decreasing 
approximately 30% and heart rate increasing by approxi-
mately 40%. Apnea was not observed in any subjects, but 
supplemental oxygen via nasal cannula (to treat SpO2  93%) 
was required for 6 of the 9 patients receiving propofol and 
all 9 patients receiving fospropofol. At 20 minutes after 
the start of infusion the PaCO2 was slightly higher in the 
group receiving fospropofol (51.1 ± 4.1 mmHg vs 48.0 ± 
3.1 mmHg.) Inorganic phosphate remained within normal 
limits (2.5–4.5 mg/dL) for the propofol group but was slightly 
elevated at 20 minutes and 60 minutes after the start of the 
fospropofol infusion (4.8 ± 4.3 and 4.7 ± 0.6 mg/dL, respec-
tively). All subjects displayed normal inorganic phosphate 
levels within 24 hours. No increase in formate concentration 
was noted in either group.
Subjectively, 3 of the 9 subjects reported pain at the injec-
tion site during the propofol trial, beginning with the initiation 
of infusion and persisting for 4 to 5 minutes. In contrast, none 
of the volunteers reported localized pain during the fospropo-
fol administration. However, all 9 volunteers reported itch-
ing, burning, and paresthesia in the anal and genital regions 
beginning 1 minute after the infusion had begun and resolving 
within 1 to 2 minutes. 2 of the subjects reported the sever-
ity as mild, 6 reported moderate symptoms, and 1 reported 
severe manifestations. Mild to moderate myoclonus was 
also noted in 3 of the 9 subjects, beginning 16 to 22 minutes 
after the start of the fospropofol infusion and lasting from 8 
to 12 minutes before spontaneous resolution.
In 2005, a study was performed using burst suppres-
sion ratio and BIS monitoring to compare and contrast the 
pharmacodynamic profiles of propofol and fospropofol.44 By 
using purely clinical data, they circumvented the SOV issue 
that had plagued prior studies. Thirty-six healthy volunteers 
were divided into 6 groups of 6 and given a bolus dose of 
fospropofol (5, 10, 15, 20, 25, or 30 mg/kg in Groups 1–6, 
respectively). The lowest BIS value (BISpeak) as well as 
the time required to obtain this level of hypnosis (TBIS, peak) 
was recorded for each subject. Hemodynamic and respira-
tory parameters were also recorded. All subjects were then 
brought back one week later and received a continuous infu-
sion of propofol (50 mg/minute) titrated to similar BISpeak as 
the prior week.
Among the 6 groups, only Groups 5 and 6 displayed a 
burst suppression ratio of greater than 10%. Both fospro-
pofol and propofol produced a dose dependent decrease 
in BISpeak, although TBIS, peak was significantly shorter when 
patients received propofol rather than fospropofol. Loss of Therapeutics and Clinical Risk Management 2009:5 955
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consciousness to verbal stimuli occurred with both drugs 
in Groups 3–6 at statistically similar BIS values and time 
measurements. It is interesting that both drugs displayed a 
statistically similar time until LOCverbal, but thereafter propo-
fol produced a TBIS, peak more quickly than fospropofol. Dura-
tion of unconsciousness increased with increasing doses of 
both drugs, but fospropofol produced a significantly longer 
LOCverbal than propofol among each cohort.
Hemodynamics were also studied for both drugs. Both 
drugs produced a transitory tachycardia (25%–40% increase 
with fospropofol, 10%–20% with propofol) within the first 
minute after administration. All cases were transient and 
resolved spontaneously. It is not known whether the change 
in heart rate was due to a pharmacodynamic effect of the 
drugs or whether the patients were reacting to an uncomfort-
able sensation (one third of the propofol patients reported 
pain at the injection site, while all 36 fospropofol patients 
reported genital and perianal paresthesias). The majority of 
subjects who received fospropofol showed a biphasic profile 
in their MAP, with 30/36 showing a small initial increase in 
MAP (10–15 mmHg) within the first minute, followed by 
a smooth drop in MAP of 20% to 25% from baseline val-
ues. As with the tachycardia, the increase in MAP may be 
attributable to the uncomfortable paresthesias experienced 
by these patients. In contrast, propofol resulted in an insig-
nificant initial rise in MAP, followed by a more rapid drop 
(compared to fospropofol) of 20% below baseline, consistent 
with prior studies.41,45
While respiratory depression was noted with both drugs, 
fospropofol (as opposed to propofol) resulted in no episodes 
of apnea among the lowest dosed group. Fospropofol did not 
result in apnea until the threshold of 15 mg/kg was reached. 
For Groups 3–6, the number of volunteers with apnea, as 
well as the duration of the apneic periods, was statistically 
increased in the propofol group compared to the fospropofol 
group.
Patients in both cohorts were also subject to a battery 
of laboratory exams. Hematologic, electrolyte, and serum 
chemistry panels showed no variation from baseline after 
administration of either drug. Formate concentration 
showed no increase above baseline even among volunteers 
receiving the highest dose of fospropofol. Levels of inor-
ganic phosphate were elevated in patients receiving the 
highest dose of fospropofol, yet they spontaneously returned 
to a normal range prior to reaching toxic levels. Ionized 
calcium remained unchanged in both cohorts. Cholesterol, 
low-density lipoprotein cholesterol, and high-density lipo-
protein cholesterol values remained stable in both groups, 
although triglyceride levels were elevated in the volunteers 
receiving the higher doses of propofol; maximum elevation 
was reached 10 minutes after the start of the infusion and 
all returned to normal thereafter. As expected, no increase 
in triglycerides was noted after the administration of 
fospropofol.
Fechner et al studied the efficacy of using a 2-hour infusion 
of fospropofol to induce a level of sedation that would theo-
retically be adequate for a minimally invasive procedure.46 
Their study group of 12 volunteers received a target controlled 
infusion (TCI) of the drug set to result in a propofol blood level 
of 1.8 µg/mL during the first hour. Again, their calculations 
rested upon data rendered inaccurate by the use of SOV and 
can only be evaluated qualitatively. Their goal during the first 
hour was to achieve a modified OAA/S (MOAA/S)47 score 
(Table 2) of 2 or 3 within 60 minutes. If any patient was out-
side of this range the dose would be adjusted either upward 
or downward during the second hour in a further attempt to 
reach the target. Physiologic monitoring including BIS was 
performed throughout the study.
After 1 hour 9 of the 12 volunteers required an upward 
titration in their fospropofol infusions to achieve a satisfac-
tory MOAA/S score. No patients required a downward titra-
tion due to oversedation. During the first hour the median 
MOAA/S score was 4 and the mean BIS was 72 ± 12. During 
the second hour the MOAAS score dropped to a median of 
3 with a corresponding decrease in the BIS to a mean value 
of 61 ± 11. Changes in systolic and diastolic blood pressure, 
heart rate, and oxygen saturation were consistent with previ-
ously published data. 11 of the 12 volunteers complained of 
genital and perianal paresthesias beginning 1 minute after 
the start of the infusion and resolving 2 minutes thereafter. 
Four volunteers rated the sensation as mild and 7 reported 
it as moderate.
Although the pharmacokinetics of the study were flawed 
there are some salient points that were not apparent from 
the previously described fospropofol bolus studies. Among 
Table 2 The Modified Observer’s Assessment of Alertness/
Sedation (MOAA/S) scale
MOAA/S score Clinical manifestations of sedation
5 Responds readily to name spoken in normal tone.
4 Lethargic response to name spoken in normal tone.
3 Responds only after name is called loudly and/or 
repeatedly.
2 Responds only after a painful trapezius squeeze.
1 Does not respond to a painful trapezius squeeze.Therapeutics and Clinical Risk Management 2009:5 956
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the nine patients who required an upward titration in their 
infusion, an increased level of sedation was reached at an 
average time of 3 minutes after the infusion rate was adjusted. 
This level of sedation was maintained during the remainder 
of the study. This suggests that fospropofol, like propofol, 
can be rapidly titrated in clinical practice to achieve a desired 
level of sedation. Recovery time after a 2-hour infusion was 
significantly higher for the fospropofol: after the 2 hour 
infusion the mean recovery time to a MOAA/S score of 5 
was 18 minutes, approximately 10 minutes longer than the 
recovery time for propofol.48
Clinical studies
Clinical studies with fospropofol have been conducted 
among patients receiving bronchoscopies or colonoscopies. 
In the former, the vast majority of the 500,000 flexible 
bronchoscopies performed annually in the United States49 
are performed under some type of intravenous sedation.50,51 
While some authors have questioned the need for sedation 
during a flexible bronchoscopy,52 the majority of clinicians 
use a combination of a benzodiazepine (to provide amnesia) 
and an opiod (to provide both analgesia and an antitussive 
effect).53 One multicenter study has suggested that fospropo-
fol may be a good alternative.54 In this study, patients were 
randomized to receive either 2 mg/kg (nontherapeutic dose) 
or 6.5 mg/kg fospropofol prior to flexible bronchoscopy. All 
patients also received fentanyl 50 µg iv and topical lidocaine 
spray. Fospropofol was redosed every 4 minutes, up to three 
times, if the MOAA/S score was 5. The primary end point of 
the study was successful sedation (defined as three consecu-
tive MOAA/S scores  4) and successful treatment (defined 
as the ability to complete the bronchoscopy without the use 
of additional sedatives or assisted ventilation). Secondary 
end points included patient satisfaction with the procedure 
(defined as the willingness to undergo a repeat bronchoscopy 
with fospropofol), amnesia for the event, and time to recovery 
from sedation.
The higher dose group fared significantly better in 
achieving both primary end points. Among the 6.5 mg/kg 
group sedation success was 88.7% vs 27.5% for the 2 mg/kg 
group (P  0.001); treatment success also heavily favored the 
higher dose group (91.3% vs 41.2%, P  0.001). The major-
ity (56%) of the 6.5 mg/kg group required no supplemental 
doses of fospropofol, and only 8 % required the addition of 
a benzodiazepine (compared to 7% and 58.8%, respectively, 
in the 2 mg/kg group). The time interval until the patient was 
adequately sedated was 4 minutes in the high dose group vs 
18 minutes in the low dose group. Secondary endpoints also 
favored the higher dose: among the 6.5 mg/kg group, 94.6% 
would be willing to repeat the procedure with fospropofol 
and 83.3% did not have any recall of the event (vs 78.2% and 
55.4%, respectively, among the 2 mg/kg group, P  0.001 for 
both). Readiness for hospital discharge was slightly prolonged 
in the higher dose group (8.5 vs 8.0 minutes) although the 
difference was statistically insignificant. (This should be 
contrasted with the 20- to 120-minute range for discharge 
readiness reported after the use of a benzodiazepine/opiod 
combination).55,56 Adverse events reported in both groups 
included pruritis, hypotension, and oxygen saturation below 
92%. All were rated by the patients and bronchoscopists as 
being mild to moderate and resolved either spontaneously 
or with minor intervention (eg, increased oxygen flow, chin 
lift, fluid bolus). The incidence of desaturation below 92% 
(15.4% in the high dose group, 12.6% in the low dose group) 
was lower than prior published studies (24-32%)57,58 using a 
benzodiazepine/opioid combination.
The number of colonoscopies performed annually far 
eclipses the number of bronchoscopies due in part to the 
former’s use as a screening tool as well as a diagnostic pro-
cedure. As with bronchoscopies, sedation has become the 
standard of care during colonoscopies59 and has been shown 
to reduce the incidence of studies aborted prematurely due to 
patient intolerance.60,61 While agents such as benzodiazepines 
and opiods are frequently relied upon, gastroenterologists 
have become increasingly attracted to the use of propofol 
during colonoscopies.62 Despite the package insert warn-
ing that propofol should be “administered only by persons 
trained in the administration of general anesthesia and not 
involved in the conduct of the surgical/diagnostic procedure”7 
gastroenterologists have been lobbying for this clause to be 
dropped, insisting that propofol can be safely administered 
by a registered nurse under the supervision of the physician 
performing the procedure.11,63–66 Both the American Society 
of Anesthesiologists and the American Association of 
Nurse Anesthetists have filed formal rebuttals arguing that 
the requested change is ill-advised.67 The small but genuine 
incidence of adverse effects, coupled with the reluctance of 
payors to compensate for the anesthesia component of routine 
colonoscopies68 has focused attention on fospropofol as being 
an all-purpose solution.
Clinical studies suggest that fospropofol may be as 
efficacious as propofol to provide rapid and safe sedation 
during routine outpatient colonoscopies.69 One study showed 
both drugs provided significant reduced time to discharge 
(and associated economic savings). In the time to complete 
1 colonoscopy using midazolam and meperidine for sedation Therapeutics and Clinical Risk Management 2009:5 957
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(71.1 minutes), the clinicians were able to complete 1.76 
colonoscopies using propofol and 1.91 using fospropofol, 
resulting in an increased profit margin of around US$67 per 
colonoscopy performed in a hospital outpatient setting, and 
US$57 per procedure performed in an ambulatory surgical 
center.70 (These figures represent the profit for the gastroen-
terologist in the absence of an anesthesia provider. When such 
a provider is present and compensated, the average profits for 
the colonoscopy drop to US$32 and US$22, respectively). 
Savings attributed to rapid recovery were not analyzed from 
the perspectives of the patients (eg, less need for childcare) 
and society (eg, fewer days absent from work).
A common thread running throughout the gastrointes-
tinal literature is that propofol (due to its lack of analgesic 
properties) is insufficient alone to provide moderate sedation 
necessary for a successful colonoscopy.71 The addition of a 
small dose of a benzodiazepine (which also has no analgesic 
properties) and/or an opiod (and possibly diphenhydramine 
as well)72 has been shown to increase patient satisfaction,73 
reduce the dose of propofol by up to 50%,74 and reduce the 
time to discharge from the recovery area.75 This practice has 
extended to include fospropofol, as evidenced by a large 
study of patients receiving fospropofol for sedation during 
colonoscopies: all patients were premedicated with fentanyl 
50 µg before initiation of the sedation regimen. Patients were 
then randomized to receive either fospropofol (2, 5, 6.5, or 
8 mg/kg) or midazolam (0.02 mg/kg).76 The goal was to 
maintain a MOAA/S score  4; if necessary fospropofol was 
redosed every 4 minutes at one-quarter of the original dose 
(for the fospropofol group) or midazolam was redosed every 
2 minutes at 1 mg increments (for the benzodiazepine group). 
Results were similar to the bronchoscopy study referenced 
earlier; patients in the 6.5 and 8 mg/kg groups had statistically 
significant greater success in sedation and treatment success 
when compared to their counterparts in the 2 and 5 mg/kg 
cohort (P  0.001). Patients in the 8 mg/kg dose group were 
much more likely to enter a state of deep sedation (defined as 
a MOAA/S score of 0 or 1) vs patients in the 6.5 mg/kg group 
(25% vs 4%, respectively). Finally, patients in the 6.5 mg/kg 
group scored higher than any other group in measurements 
of patient satisfaction and willingness to repeat the procedure 
with the same method of sedation. No serious adverse effects 
were noted in any of the groups, and again the principle patient 
complaint was mild to moderate paresthesia.
Conclusions
Monitored anesthesia care provides a valuable bridge 
between moderate sedation, (which may be inadequate for 
a given procedure) and general anesthesia (which may be 
unnecessary). Under the direction of an anesthesiologist the 
patient can be both medically managed and safely sedated to 
allow for successful completion of the procedure. Fospropo-
fol may prove to be a useful tool for the anesthesia provider, 
offering many of the benefits of propofol while eschewing 
several of the concomitant side effects. The most prevalent 
side effect of fospropofol, genital and perianal itching, has 
not interfered with the widespread clinical adoption of other 
phosphorylated prodrugs (eg, phosphenytoin) which share 
the same side effect profile.77
In mid-December 2008 the FDA approved fospropofol 
for use in monitored anesthesia care settings.78 Due to a 
series of corporate takeovers, fospropofol (GPI 15715; 
Aquavan®) will be marketed by the Eisai Corporation of 
North America under the trade name Lusedra®. Like pro-
pofol, the FDA has mandated that Lusedra® be used only by 
persons trained in the administration of general anesthesia, 
and that all patients should be continuously monitored by 
persons not involved in the conduct of the procedure.79 
The fact that fospropofol is not an induction agent has led 
some pulmonologists to feel it is safe to circumvent the 
requirement for trained anesthesia personnel during its 
administration.80 Other clinicians may join their chorus and 
petition the FDA for more liberal labeling. Some speculate 
that the FDA may proceed in a diametrically opposite 
direction, petitioning the DEA to classify Lusedra® as a 
controlled substance.81 We agree that while fospropofol is 
not an induction agent, the possibility exists that a patient 
may still proceed to an unintended depth of sedation. 
Given that risk, and the concomitant risk of aspiration and 
cardiopulmonary compromise, we believe that (as with 
propofol) the use of fospropofol should be limited to those 
clinicians trained in the practice of general anesthesia and 
rescue techniques. However the FDA proceeds, fospropofol 
should prove to be a useful adjunct for anesthesia providers 
administering monitored anesthesia care.
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